Chinese biopharmaceutical firm Wuxi AppTec has taken the first step to relist its assets in Asia, launching a HK$3.6 billion to HK$4 billion ($461m to $511 million) initial public offering for its biologics division in Hong Kong on Wednesday.
¬ Haymarket Media Limited. All rights reserved.
